No beneficial effects of amantadine in treatment of chronic hepatitis C patients

Published:December 17, 2009DOI:



      Benefit of adding amantadine to antiviral therapy for hepatitis C is controversial.


      We aimed to examine whether such policy enhances sustained viral response in treatment-naïve patients.


      297 naïve hepatitis C patients were randomized for treatment with amantadine 200 mg or placebo, combined with weight-based ribavirin and 12-day high-dose interferon alpha-2b induction therapy, followed by PEG-interferon alpha-2b (1.5 μg/kg/week up to 26 weeks and thereafter, 1.0 μg/kg/week until week 52). Treatment was discontinued if hepatitis C virus (HCV) RNA was positive at week 24.


      49% of patients were (former) drug users. Genotype 1 occurred in 45%, high viral load in 70% and severe fibrosis/cirrhosis in 32%, without differences between amantadine or placebo groups. 90 patients prematurely discontinued treatment, mainly because of grade 3 or 4 toxicity. Intention-to-treat analysis revealed sustained viral response in 47% and 51% of amantadine and placebo groups (p = 0.49). Amantadine did not enhance sustained viral response in patients with genotype 1 or high viral load nor did it improve primary non-response, breakthrough or relapse rates. Genotype non-1 and lower pre-treatment γGT levels were independent predictors for sustained viral response.


      Adding amantadine to antiviral therapy of previously untreated chronic hepatitis C patients has no beneficial effects.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alter M.J.
        • Kruszon-Moran D.
        • Nainan O.V.
        • et al.
        The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.
        N Engl J Med. 1999; 341: 556-562
        • Fried M.W.
        • Shiffman M.L.
        • Reddy K.R.
        • et al.
        Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
        N Engl J Med. 2002; 347: 975-982
        • Manns M.P.
        • McHutchison J.G.
        • Gordon S.C.
        • et al.
        Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
        Lancet. 2001; 358: 958-965
        • Dolin R.
        • Reichman R.C.
        • Madore H.P.
        • et al.
        A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.
        N Engl J Med. 1982; 307: 580-584
        • Koff W.C.
        • Elm Jr., J.L.
        • Halstead S.B.
        Inhibition of dengue virus replication by amantadine hydrochloride.
        Antimicrob Agents Chemother. 1980; 18: 125-129
        • Reuman P.D.
        • Bernstein D.I.
        • Keefer M.C.
        • et al.
        Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A.
        Antiviral Res. 1989; 11: 27-40
        • Van Voris L.P.
        • Betts R.F.
        • Hayden F.G.
        • et al.
        Successful treatment of naturally occurring influenza A/USSR/77 H1N1.
        J Am Med Assoc. 1981; 245: 1128-1131
        • Tabone M.
        • Ercole E.
        • Zaffino C.
        • et al.
        Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients.
        Ital J Gastroenterol Hepatol. 1998; 30: 611-613
        • Caronia S.
        • Bassendine M.F.
        • Barry R.
        • et al.
        Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study.
        J Hepatol. 2001; 35: 512-516
        • Mangia A.
        • Leandro G.
        • Helbling B.
        • et al.
        Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.
        J Hepatol. 2004; 40: 478-483
        • Brillanti S.
        • Foli M.
        • Di T.M.
        • et al.
        Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
        Ital J Gastroenterol Hepatol. 1999; 31: 130-134
        • Smith J.P.
        Treatment of chronic hepatitis C with amantadine.
        Dig Dis Sci. 1997; 42: 1681-1687
        • Berg T.
        • Kronenberger B.
        • Hinrichsen H.
        • et al.
        Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
        Hepatology. 2003; 37: 1359-1367
        • Helbling B.
        • Stamenic I.
        • Viani F.
        • et al.
        Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.
        Hepatology. 2002; 35: 447-454
        • Mangia A.
        • Minerva N.
        • Annese M.
        • et al.
        A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
        Hepatology. 2001; 33: 989-993
        • Tabone M.
        • Laudi C.
        • Delmastro B.
        • et al.
        Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients.
        J Hepatol. 2001; 35: 517-521
        • Steinmann E.
        • Whitfield T.
        • Kallis S.
        • et al.
        Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.
        Hepatology. 2007; 46: 330-338
        • Dienstag J.L.
        • McHutchison J.G.
        American Gastroenterological Association technical review on the management of hepatitis C.
        Gastroenterology. 2006; 130: 231-264
        • Mangia A.
        • Ricci G.L.
        • Persico M.
        • et al.
        A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs. interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C.
        J Viral Hepat. 2005; 12: 292-299
        • Angelico M.
        • Koehler-Horst B.
        • Piccolo P.
        • et al.
        Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C.
        Eur J Gastroenterol Hepatol. 2008; 20: 680-687
        • von Wagner M.
        • Hofman P.
        • Teuber G.
        • et al.
        Randomized, double-blind, placebo-controlled trial of Peginterferon alfa-2a (40 kD) and ribavirin with and without 400 mg amantadine-sulphate for 48 weeks in treatment naive HCV genotype 1-infected patients.
        Hepatology. 2007; 46: S1342
        • Deltenre P.
        • Henrion J.
        • Canva V.
        • et al.
        Evaluation of amantadine in chronic hepatitis C: a meta-analysis.
        J Hepatol. 2004; 41: 462-473
        • Teuber G.
        • Pascu M.
        • Berg T.
        • et al.
        Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
        J Hepatol. 2003; 39: 606-613
        • Zeuzem S.
        Induction therapy in chronic hepatitis C: deja-vu with pegylated interferons?.
        J Hepatol. 2004; 41: 488-490
        • Dixit N.M.
        • Layden-Almer J.E.
        • Layden T.J.
        • et al.
        Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.
        Nature. 2004; 432: 922-924
        • Lindsay K.L.
        • Trepo C.
        • Heintges T.
        • et al.
        A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
        Hepatology. 2001; 34: 395-403
        • Silva I.S.
        • Ferraz M.L.
        • Perez R.M.
        • et al.
        Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection.
        J Gastroenterol Hepatol. 2004; 19: 314-318
        • Bedossa P.
        • Dargere D.
        • Paradis V.
        Sampling variability of liver fibrosis in chronic hepatitis C.
        Hepatology. 2003; 38: 1449-1457